GGHC
IBRX icon

Gilder Gagnon Howe & Co’s ImmunityBio IBRX Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-48,511
Closed -$841K – 248
2015
Q4 		$841K Buy
48,511
+46,045
+1,867% +$683K 0.01% 182
2015
Q3 		$28K Buy
+2,466
New +$53.8K ﹤0.01% 246

Other funds holding IBRX

WCM
Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return
CC
Callan Capital La Jolla, California $1.35B AUM 8.35% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Gilder Gagnon Howe & Co's IBRX Position: Q1 2016 in Review

Gilder Gagnon Howe & Co sold out of ImmunityBio (IBRX) in Q1 2016, closing a stake of 48,511 shares — an estimated $841K sold.

Gilder Gagnon Howe & Co first reported a position in IBRX in Q3 2015 and held it in 2 quarters. The position peaked at $841K in Q4 2015. 62 funds tracked by Wall St. Rank hold IBRX as of Q1 2016.

  • Gilder Gagnon Howe & Co reported no remaining ImmunityBio position as of Q1 2016 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 48,511 ImmunityBio shares in Q1 2016, an estimated $841K.
  • Gilder Gagnon Howe & Co first reported a position in ImmunityBio in Q3 2015 and held it in 2 quarters.
  • Gilder Gagnon Howe & Co's ImmunityBio position peaked at $841K in Q4 2015.
  • 62 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2016.

Based on Gilder Gagnon Howe & Co's 13F filing for Q1 2016, filed 3 May 2016.